Cargando…

PK/PD Modeling of the PDE7 Inhibitor—GRMS-55 in a Mouse Model of Autoimmune Hepatitis

This study aimed to assess the efficacy and explore the mechanisms of action of a potent phosphodiesterase (PDE)7A and a moderate PDE4B inhibitor GRMS-55 in a mouse model of autoimmune hepatitis (AIH). The concentrations of GRMS-55 and relevant biomarkers were measured in the serum of BALB/c mice wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Świerczek, Artur, Plutecka, Hanna, Ślusarczyk, Marietta, Chłoń-Rzepa, Grażyna, Wyska, Elżbieta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143339/ https://www.ncbi.nlm.nih.gov/pubmed/33919375 http://dx.doi.org/10.3390/pharmaceutics13050597

Ejemplares similares

Comparative Assessment of the New PDE7 Inhibitor – GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach
por: Świerczek, Artur, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases
por: Świerczek, Artur, et al.
Publicado: (2022)

Evaluation of analgesic and anti-inflammatory activity of purine-2,6-dione-based TRPA1 antagonists with PDE4/7 inhibitory activity
por: Zygmunt, Małgorzata, et al.
Publicado: (2022)

A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling
por: Wójcik-Pszczoła, Katarzyna, et al.
Publicado: (2020)

PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response
por: Świerczek, Artur, et al.
Publicado: (2017)

Anti‐inflammatory effects of dexamethasone in COVID‐19 patients: Translational population PK/PD modeling and simulation
por: Świerczek, Artur, et al.
Publicado: (2023)

Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice
por: Wyska, Elżbieta, et al.
Publicado: (2015)

Pan-Phosphodiesterase Inhibitors Attenuate TGF-β-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation
por: Wójcik-Pszczoła, Katarzyna, et al.
Publicado: (2022)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

In Vitro Biotransformation, Safety, and Chemopreventive Action of Novel 8-Methoxy-Purine-2,6-Dione Derivatives
por: Marć, Małgorzata Anna, et al.
Publicado: (2017)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

Antiplatelet Effects of Selected Xanthine-Based Adenosine A(2A) and A(2B) Receptor Antagonists Determined in Rat Blood
por: Kubacka, Monika, et al.
Publicado: (2023)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Efficacy of the Multi-Target Compound E153 in Relieving Pain and Pruritus of Different Origins
por: Mogilski, Szczepan, et al.
Publicado: (2023)

Prediction of Clinical Irrelevance of PK Differences in Atorvastatin Using PK/PD Models Derived From Literature-Based Meta-Analyses
por: Vargo, R, et al.
Publicado: (2014)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

PK/PD modeling of Ceftiofur Sodium against Haemophilus parasuis infection in pigs
por: Li, Xiao-dong, et al.
Publicado: (2019)

Comparing Model Performance in Characterizing the PK/PD of the Anti‐Myostatin Antibody Domagrozumab
por: Tiwari, Abhinav, et al.
Publicado: (2019)

Multivariate Exact Discrepancy: A New Tool for PK/PD Model Evaluation
por: Baklouti, Sarah, et al.
Publicado: (2023)

Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
por: Zhang, Wantong, et al.
Publicado: (2018)

Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling
por: Jacqmin, Philippe, et al.
Publicado: (2010)

Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction
por: Ahmad, Ijaz, et al.
Publicado: (2016)

PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
por: Lei, Zhixin, et al.
Publicado: (2018)

A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs
por: Singh, Aman P., et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer
por: Yao, Qing-yu, et al.
Publicado: (2019)

PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against Streptococcus suis in Piglets
por: Huang, Anxiong, et al.
Publicado: (2022)

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
por: Grant, Joshuaine, et al.
Publicado: (2023)

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria
por: Oh, Elise, et al.
Publicado: (2023)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

PK/PD Modeling to Assess Rifaximin Clinical Dosage in a Mouse Model of Staphylococcus aureus-Induced Mastitis
por: Wang, Honglei, et al.
Publicado: (2021)

Alternaria alternata induced inflammatory lung responses: a novel in vivo PK/PD model
por: Gil, Malgorzata, et al.
Publicado: (2013)

Correlation of PK/PD Indices with Resistance Selection for Cefquinome against Staphylococcus aureus in an In Vitro Model
por: Li, Yafei, et al.
Publicado: (2016)

Vertical Integration of Pharmacogenetics in Population PK/PD Modeling: A Novel Information Theoretic Method
por: Knights, J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_djl5289g5ja8qoidiuv7pqhn7q